Abstract
A rapid, sensitive and selective liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for the identification and determination of olanzapine (OLZ, CAS 132539-06-1) in human plasma. Following liquid- liquid extraction, OLZ and loratadine (IS, CAS 79794-75-5) were separated using a mobile phase consisting of acetonitrile: aqueous ammonium acetate solution (pH 4.0, 10 mM) = 56:44 (v/v) on an Agilent ZORBAX Eclipse XDB-CN (2.1mmx150mm I.D., 5μm) column and analyzed by electrospray ionization mass spectrometry in the selected ion monitoring (SIM) mode using the respective [M+H]+ ions, m/z 313.15 for OLZ and m/z 383.00 for loratadine. The chromatographic separation was achieved in less than 6.0 min. The assay exhibited a linear dynamic range of 0.5–50 ng/ml for OLZ in human plasma and had good accuracy and precision. Both intra- and inter-batch standard deviations were less than 15%. The validated LC–MS method was first applied to a bioequivalence study in 20 healthy male Chinese volunteers.
Keywords: Application, Bioequivalence, Chinese volunteers, Determination, Identification, Human plasma, LC-MS, Loratadine, Olanzapine, Pharmacokinetics
Current Pharmaceutical Analysis
Title:Liquid Chromatography-Mass Spectrometry Method for the Determination of Olanzapine in Human Plasma and Application to a Bioequivalence Study
Volume: 8 Issue: 3
Author(s): Jing Cao, Zunjian Zhang, Yuan Tian, Yuanyuan Li and Jianzhong Rui
Affiliation:
Keywords: Application, Bioequivalence, Chinese volunteers, Determination, Identification, Human plasma, LC-MS, Loratadine, Olanzapine, Pharmacokinetics
Abstract: A rapid, sensitive and selective liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for the identification and determination of olanzapine (OLZ, CAS 132539-06-1) in human plasma. Following liquid- liquid extraction, OLZ and loratadine (IS, CAS 79794-75-5) were separated using a mobile phase consisting of acetonitrile: aqueous ammonium acetate solution (pH 4.0, 10 mM) = 56:44 (v/v) on an Agilent ZORBAX Eclipse XDB-CN (2.1mmx150mm I.D., 5μm) column and analyzed by electrospray ionization mass spectrometry in the selected ion monitoring (SIM) mode using the respective [M+H]+ ions, m/z 313.15 for OLZ and m/z 383.00 for loratadine. The chromatographic separation was achieved in less than 6.0 min. The assay exhibited a linear dynamic range of 0.5–50 ng/ml for OLZ in human plasma and had good accuracy and precision. Both intra- and inter-batch standard deviations were less than 15%. The validated LC–MS method was first applied to a bioequivalence study in 20 healthy male Chinese volunteers.
Export Options
About this article
Cite this article as:
Cao Jing, Zhang Zunjian, Tian Yuan, Li Yuanyuan and Rui Jianzhong, Liquid Chromatography-Mass Spectrometry Method for the Determination of Olanzapine in Human Plasma and Application to a Bioequivalence Study, Current Pharmaceutical Analysis 2012; 8 (3) . https://dx.doi.org/10.2174/157341212801619351
DOI https://dx.doi.org/10.2174/157341212801619351 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association between the Regulator of G-protein Signaling 9 Gene and Patients with Methamphetamine Use Disorder and Schizophrenia
Current Neuropharmacology The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews A Review on Emerging Drug Targets in Treatment of Schizophrenia
Current Drug Targets Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Drug-Induced Impulse Control Disorders: A Review
Current Clinical Pharmacology Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design Conditioned Avoidance Response in the Development of New Antipsychotics
Current Pharmaceutical Design Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Current Psychopharmacology Serum Vitamin E (α-Tocopherol) Estimation: A Potential Biomarker of Antioxidant Status Evaluation on Heavy Metal Toxicities
Recent Patents on Biomarkers Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling
Current Medicinal Chemistry - Central Nervous System Agents Antidepressant Related Movement Disorders in the Elderly
Current Psychiatry Reviews Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism